fda semaglutide shortage resolved feb 21 2025 GLP-1 = Over fda declaratory order semaglutide shortage

Data availability The data that support the findings of this study are not openly available for reasons of sensitivity, but are available from the corresponding author upon reasonable request

The study isnt yet peer-reviewed, but it appears to show retatrutide leaving other GLP-1s in the dust: The highest dose made patients lose an average of 28% of their body mass after 80 weeks, running nearly a full lap around the highest dose of Novo Nordisks Wegovy (~15% weight loss after 68 weeks)

However, the incidence and severity vary considerably between individuals, and causality remains incompletely understood

Its most commonly found in African Americans, Hispanics/Latinos, and Asians, while its less common in people of European descent